The main thing that the Oncology Care Model (OCM) has brought is a shift in the mindset, said Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
The main thing that the Oncology Care Model (OCM) has brought is a shift in the mindset, said Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
Transcript
Does participating in value-based models like the Oncology Care Model help with the practice transformation needed for practices to have sustainable growth?
When you think about the OCM and what it’s brought to practices, I think the main thing it’s brought is a shift in the mindset. It has actually allowed practices to think about their practice differently and approach it differently. We look at technology differently now because before technology was seen as a nuisance, but with the value-based contracts and value-based arrangements, technology really allows you to get done what you need to get done. So, I think it has helped us in that way.
I think it has also helped the overall market because OCM came along and introduced a change throughout the market that wasn’t available prior. So, I think there we’ve seen a tremendous growth in opportunity, and we find that a lot of the other payers, commercial payers, are following the OCM to some degree.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More